Percentage of participants with adverse events of special interest (AESIs) from study vaccination through the end of the study;Percentage of participants with each abnormal clinical safety laboratory finding for 8 days after study vaccination;Percentage of participants with medically attended adverse events (MAAEs) from study vaccination through the end of the study;Percentage of participants with serious adverse events (SAEs) from study vaccination through the end of the study;Percentage of participants with solicited local adverse events (AE) during 7 days after vaccination;Percentage of participants with solicited systemic AE during 7 days after vaccination;Percentage of participants with unsolicited AEs for 28 days after study vaccination

Percentage of participants with adverse events of special interest (AESIs) from study vaccination through the end of the study;Percentage of participants with each abnormal clinical safety laboratory finding for 8 days after study vaccination;Percentage of participants with medically attended adverse events (MAAEs) from study vaccination through the end of the study;Percentage of participants with serious adverse events (SAEs) from study vaccination through the end of the study;Percentage of participants with solicited local adverse events (AE) during 7 days after vaccination;Percentage of participants with solicited systemic AE during 7 days after vaccination;Percentage of participants with unsolicited AEs for 28 days after study vaccination